Erythromycin Propionate

Summary

Erythromycin Propionate (CHEMBL2220427) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 790 Da · C40H71NO14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2220427
Name	Erythromycin Propionate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71277
ChEBI	CHEBI:48913
Molecular formula	C40H71NO14
Molecular weight	790
InChIKey	TYQXKHPOXXXCTP-CSLYCKPJSA-N

SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O

IUPAC name: [(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] propanoate

Also known as: Erythromycin propionate, Erythromycin, 2’-propionate, Monopropionylerythromycin, Propiocine, Erythromycin Propionate, ERYTHROMYCIN PROPIONATE, SID144206740, SID170465433, ERYTHROMYCIN ESTOLATE, erythromycin propionate

Parent form; salt/anhydrous children: CHEMBL2218877

Patent coverage: 460 distinct patent families (1,732 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: D(1A) dopamine receptor, Progesterone receptor, 5-hydroxytryptamine receptor 1A, Sodium-dependent noradrenaline transporter, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).